20-F: AstraZeneca Names KPMG as New External Auditor

AstraZeneca appoints KPMG as its external auditor, replacing PricewaterhouseCoopers after a competitive tender process.

Summary

• AstraZeneca has appointed KPMG LLP as its new external auditor for the fiscal year ending December 31, 2026, following a rigorous audit tender process.
• The appointment was recommended by the Audit Committee and endorsed by the Board of Directors.
• Shareholders will vote to approve the appointment at the 2026 Annual General Meeting.
• PricewaterhouseCoopers LLP (PwC) will be dismissed at the conclusion of the Company's 2026 Annual General Meeting, having served as the independent auditor since the year ended December 31, 2017.
• PwC's reports on the company's financial statements and internal controls over financial reporting for the fiscal years ended December 31, 2023, 2024 and 2025 did not contain any adverse opinions, disclaimers of opinion, qualifications, or modifications.
• There were no disagreements between AstraZeneca and PwC during the fiscal years ended December 31, 2023, 2024 and 2025 regarding any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral announcement with positive undertones. The change in auditor appears to be a well-managed transition, and the confirmation of no prior disagreements with PwC is reassuring.

Positives

• The transition to a new auditor is being managed in a structured way, with PwC continuing as the auditor for the year ending December 31, 2025.
• PwC confirmed agreement with the statements made in the filing concerning their firm.
• The filing confirms that there were no disagreements with the previous auditor, PwC, regarding accounting principles, practices, or auditing scope.

Negatives

• There are no negatives in this filing.

Risks

• There are no risks in this filing.

Future Outlook

The filing outlines the transition to KPMG as the new external auditor for the fiscal year ending December 31, 2026, with a shareholder vote scheduled at the 2026 Annual General Meeting.

Industry Context

StockSavvy.ai notes that changing auditors is a routine part of corporate governance, and this announcement reflects AstraZeneca's commitment to best practices in financial oversight. The competitive tender process suggests a focus on cost-effectiveness and quality of service.

Corporate Governance

Stakeholder Impact

• Shareholders: The change in auditor is unlikely to have a significant impact on shareholders, as it is a routine part of corporate governance.
• Employees: The change in auditor is unlikely to have a significant impact on employees.
• Customers: The change in auditor is unlikely to have a significant impact on customers.
• Suppliers: The change in auditor is unlikely to have a significant impact on suppliers.
• Creditors: The change in auditor is unlikely to have a significant impact on creditors.

Next Steps

• Shareholder vote at the 2026 Annual General Meeting to approve the appointment of KPMG.
• PwC to be dismissed at the conclusion of the 2026 Annual General Meeting.
• KPMG to commence as AstraZeneca's external auditor for the fiscal year ending December 31, 2026.

Key Dates

Recommendation

The change of auditor is a routine event and does not provide a basis for changing a recommendation on the stock.

Keywords

AstraZeneca, KPMG, PwC, auditor, financial reporting, SEC filing, external auditor, audit committee, corporate governance